On October 2, ZAI LAB fell 6.15% in regular trading, trading at 19.26 HKD/share, with turnover of approximately 7.56 million HKD, as the broader biotechnology sector came under significant selling pressure.

The decline came amid a sector-wide selloff in biotech names. Within the Biotechnology sector, BEONE MEDICINES fell 6.92%, 3SBIO fell 5.91%, SKB BIO fell 5.54%, INNOVENT BIO fell 5.05%, and AKESO fell 4.51%, reflecting broad-based weakness across the board.

On the fundamental side, ZAI LAB's previously reported interim results weighed on sentiment. The company posted a net loss of $102 million for the first half, widening 14% year-over-year, while net product revenue declined 6% to $201 million, primarily dragged down by Zejula revenue erosion from generic olaparib entering centralized procurement and Vyvgart price reductions tied to national reimbursement list renewal. R&D expenses rose 14% to $127 million due to increased licensing fees.

Institutional positioning has also diverged. JPMorgan reduced its long position to 10.7% after offloading approximately 6.02 million shares at an average price of 20.57 HKD on September 18. Meanwhile, Goldman Sachs disclosed simultaneous increases in both long and short positions on September 22, with its long stake rising to 5.49%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)